- Home
- NMM vs NRIX Comparison
NMM vs NRIX Comparison
Compare NMM & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMM
- NRIX
- Stock Information
- Founded
- NMM 2007
- NRIX 2009
- Country
- NMM Greece
- NRIX United States
- Employees
- NMM N/A
- NRIX N/A
- Industry
- NMM Marine Transportation
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- NMM Consumer Discretionary
- NRIX Health Care
- Exchange
- NMM Nasdaq
- NRIX Nasdaq
- Market Cap
- NMM 1.1B
- NRIX 908.0M
- IPO Year
- NMM 2007
- NRIX 2020
- Fundamental
- Price
- NMM $38.63
- NRIX $12.73
- Analyst Decision
- NMM Strong Buy
- NRIX Strong Buy
- Analyst Count
- NMM 1
- NRIX 16
- Target Price
- NMM $80.00
- NRIX $30.44
- AVG Volume (30 Days)
- NMM 99.9K
- NRIX 747.9K
- Earning Date
- NMM 08-19-2025
- NRIX 07-10-2025
- Dividend Yield
- NMM 0.52%
- NRIX N/A
- EPS Growth
- NMM N/A
- NRIX N/A
- EPS
- NMM 11.16
- NRIX N/A
- Revenue
- NMM $1,319,623,000.00
- NRIX $56,417,000.00
- Revenue This Year
- NMM N/A
- NRIX $16.69
- Revenue Next Year
- NMM $7.93
- NRIX N/A
- P/E Ratio
- NMM $3.46
- NRIX N/A
- Revenue Growth
- NMM 0.28
- NRIX N/A
- 52 Week Low
- NMM $28.37
- NRIX $8.18
- 52 Week High
- NMM $65.89
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- NMM 48.79
- NRIX 62.83
- Support Level
- NMM $36.62
- NRIX $11.34
- Resistance Level
- NMM $39.41
- NRIX $12.90
- Average True Range (ATR)
- NMM 1.18
- NRIX 0.66
- MACD
- NMM -0.24
- NRIX 0.02
- Stochastic Oscillator
- NMM 32.28
- NRIX 90.17
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.